Medpace exec. VP Burwig sells $13.54M in shares

Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings, Inc. (NASDAQ:MEDP), sold a total of 20,000 shares of the company’s common stock across two transactions in late October. The sales, which occurred on October 26 and October 27, 2026, collectively amounted to approximately $13.54 million.

The shares were sold at a price of $677.00 per share. These transactions were executed pursuant to a limit order placed by Ms. Burwig during an open window period. The timing coincides with Medpace trading near its 52-week high of $693.97, with the stock currently at $692.68. The company has delivered a strong 67% return over the past six months, though InvestingPro analysis suggests the stock is overvalued relative to its Fair Value—placing it among companies on the most overvalued list.

Concurrently, on October 26, 2026, Ms. Burwig also exercised employee stock options to acquire 328 shares of Medpace common stock. These shares were obtained at an exercise price of $166.73 per share, totaling $54,687. The option that was exercised had vested in full on October 27, 2025.

Following these reported transactions, Ms. Burwig directly beneficially owns 54,012 shares of Medpace Holdings, Inc. common stock. The changes in beneficial ownership were filed on October 28, 2026. For deeper insights into Medpace’s valuation and executive activity, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Medpace Holdings reported robust third-quarter 2026 earnings, surpassing Wall Street expectations. The company achieved an adjusted profit of $4.84 per share, exceeding the estimated $4.44, and generated revenue of $716 million, slightly above the forecast of $714.47 million. Revenue increased by 8.5% compared to the previous year, while net income rose by 23.7%. The EBITDA margin also improved, reaching 24.0%. Medpace’s management has raised its full-year 2026 revenue and profit guidance, reflecting confidence in the company’s ongoing performance. Additionally, the company announced that net new business awards hit a record high during the quarter. However, the release of 2027 guidance has been postponed until February, as the company continues to assess the evolving outlook on awards and cancellations.